Biotech Acquisition Company (BIOT) to Combine with Blade Therapeutics

Biotech (NASDAQ:BIOT) has entered into a definitive agreement to combine with drug developer Blade Therapeutics at an enterprise value of $352.8 million. San Francisco-based Blade Therapeutics is developing three drug candidates as potential therapies against varying forms of organ fibrosis with its most advanced having completed Phase I. The combined company is expected to trade
Read More